March 3, 2026Open Access

Cost-effectiveness of novel antiandrogens for the treatment of nmCRPC patients in the Chinese healthcare system

Puntos clave

Apalutamide plus androgen deprivation therapy (ADT) is more cost-effective than bicalutamide plus ADT.
Darolutamide combined with ADT also shows better cost-effectiveness compared to bicalutamide plus ADT.
Enzalutamide plus ADT is not cost-effective versus bicalutamide plus ADT at the specified willingness-to-pay threshold.
Findings suggest that apalutamide and darolutamide are favorable options for nmCRPC treatment in the Chinese healthcare system.

Resumen

Compared with bicalutamide plus ADT, apalutamide plus ADT and darolutamide plus ADT are more cost-effective under the willingness-to-pay threshold of 38, 223/QALY. Nonetheless, enzalutamide plus ADT is not cost-effective compared with bicalutamide plus ADT.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo